Cardiovascular Disease Clinical Trial
— FISHDISHOfficial title:
FIsh for a Sustainable Healthy Diet In Scottish Households Study
Verified date | March 2016 |
Source | University of Aberdeen |
Contact | n/a |
Is FDA regulated | No |
Health authority | United Kingdom: Research Ethics Committee |
Study type | Interventional |
Consumption of fish can help to prevent cardiovascular disease. The precise way in which
fish is beneficial is not fully understood. This is important to find out as fish consists
of a complex mixture of fatty acids and micronutrients such as vitamin D and selenium that
could individually, or collectively, be responsible for the beneficial effects.
Fish farming in Scotland is playing an increasingly important role in the provision of fish
for human consumption. But issues with sustainability of raw materials are requiring fish
farming to reformulate fish diets, which may affect the levels of beneficial omega-3 fatty
acids and other components in fish.
In this study we will be comparing the long-term health effects of eating two portions a
week of Scottish salmon raised on a traditional fish diet versus eating two portions a week
of Scottish salmon raised on a more sustainable fish diet. In addition, we will be looking
at differences in health outcomes when eating two portions a week of either Scottish salmon,
compared with eating no fish at all.
Status | Completed |
Enrollment | 51 |
Est. completion date | March 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 35 Years to 75 Years |
Eligibility |
Inclusion criteria: Healthy men and women aged 35-75 years BMI ranging from 18-35 kg/m2
Blood pressure below 160/90 mmHg; Total cholesterol < 8.00 mmol/L Total/HDL cholesterol <
6 mmol/L Fasting plasma glucose , 7 mmol/L Having a 10-20% risk for developing
cardiovascular disease within the next 10 years based on the ASSIGN calculation
(http://cvrisk.mvm.ed.ac.uk/index.htm) including the following factors: age, gender,
number of cigarettes smoked per day, Scottish Index of Multiple Deprivation
(SIMD)/postcode, systolic blood pressure, levels of total and HDL cholesterol and family
history of cardiovascular disease, or having at least one additional risk factor such as
being over 50 years old, BMI above 25 kg/m2, elevated triglyceride levels (> 1.7 mmol/L)
or elevated glucose levels (> 5.6 mmol/L); platelet count > 1709/L haematocrit above 40 %
for males and above 35 % for females haemoglobin above 130 g/L for males and above 115 g/L
for females Exclusion criteria Regularly taking aspirin or aspirin-containing drugs, or other anti-inflammatory drugs; Taking drugs or herbal medicines known to alter the haemostatic system in general; Taking any medicine known to affect lipid metabolism; Taking certain dietary supplements/multivitamin tablets; Diagnosis of diabetes, hypertension, renal, hepatic, haematological disease or coronary heart disease; Unsuitable veins for blood sampling; Inability to understand the participant information sheet; inability to speak, read and understand the English language. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United Kingdom | Rowett Institute of Nutrition and Health, Human Nutrition Unit | Aberdeen |
Lead Sponsor | Collaborator |
---|---|
University of Aberdeen |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Bleeding time as measured by the platelet function analyzer (PFA-100) | The PFA-100 simulates high shear platelet function in citrated blood within disposable test cartridges with membranes coated with either collagen/epinephrine (CEPI) or collagen/ADP (CADP). The presence of these platelet activators and the high shear rates under the standardised conditions result in platelet adhesion, activation and aggregation resulting in formation of a platelet plug within the aperture. Platelet function is thus measured as a function of the time it takes to occlude the aperture. | At baseline and after 18 weeks salmon consumption | No |
Other | Markers of coagulation and endothelial activation. | Fibrinogen is a principle plasma glycoprotein involved in blood clotting. Plasma clottable fibrinogen levels will be measured by Clauss method on a semi-automated coagulometer using Fibrinogen assay thrombin reagent from Helena Biosciences, England. Von Willebrand factor (vWF) is another plasma glycoprotein involved in coagulation and an established marker of endothelial activation or damage. Plasma levels of vWF will be measured by an in-house ELISA using polyclonal antibodies and horseradish peroxidase-conjugated antibody from DAKO Ltd, Denmark. P-selectin is a cell adhesion molecule present in platelet granules and (to a lesser extent) in endothelial cells. sP-selectin levels in fasted blood plasma will be measured in duplicate by ELISA (Bender Med Systems) | At baseline and after 18 weeks salmon consumption | No |
Other | Markers of inflammation. | CRP is an acute phase protein synthesised by the liver in response to inflammatory stimuli, especially the cytokine IL-6. hsCRP will be measured in duplicate by an ultra sensitive, double antibody ELISA. Soluble -ICAM is a marker of endothelial activation and inflammation, during which it promotes leucocyte adherence to the endothelium. Plasma soluble I-CAM levels will be measured in duplicate by ELISA (Bender Med Systems). Epoxyeicosatrieonic acids (EETs) are anti-inflammatory and cardioprotective compounds. Their availability and metabolism are regulated by the enzyme soluble epoxide hydrolase (sEH), which in turn is affected by EPA. EETs will be measured in platelets using LC-MS/MS. | At baseline and after 18 weeks salmon consumption | No |
Other | Markers of oxidative stress. | F2-isoprostanes are currently considered as reference biomarkers for lipid peroxidation and will be measured by LC-MS/MS. | At baseline and after 18 weeks salmon consumption | No |
Other | Markers of micronutrient availability | Selenium in incorporated into proteins within the body, many of which are antioxidants that protect the body against oxidative damage. Selenium is transported across the body within the protein, selenoprotein P (SEPP-1). Selenium status will be measured by assaying plasma selenium levels (by ICP-MS) and by quantification of plasma SEPP-1 levels (by an in-house ELISA). Iodine status will be measured by assaying urinary iodine levels (by ICP-MS) and vitamin D status will be assessed by measuring plasma 25-hydroxy vitamin D (using HPLC and LC/MS/MS). | At baseline and after 18 weeks salmon consumption | No |
Other | Markers of gut health | Faecal samples will be collected for the isolation of faecal waters to measure NFkb activation, micronutrient levels, genetic health and antioxidant potential (ORAC, TRAC etc), as well as the measurement of stool content and stool pH. | At baseline and after 18 weeks salmon consumption | No |
Other | Markers of genetic health | The buffy coat from spun whole blood samples will be collected to measure patterns of DNA methylation contributing to epigenetic inheritance. | At baseline and after 18 weeks salmon consumption | No |
Primary | Change in the omega-3 index | The Omega-3 index will be measured by GC-MS. An optimal target level of the Omega-3 Index is 8%, and an undesirable level is less than 4%, with 4-8% being an intermediate-risk zone. | At baseline and after 18 weeks salmon consumption | No |
Secondary | Change in cardiovascular risk markers | This study will include the measurement of standard risk markers of cardiovascular disease at the start, middle and end of the intervention period, including lipoprotein metabolism (total cholesterol, LDL cholesterol, HDL cholesterol) and metabolic markers (glucose, insulin, triglycerides and non-esterified fatty acids to calculate HOMA-IR and revised QUICKI). We will also measure 24-hrs ambulatory blood pressure. | At baseline, after 9 weeks and after 18 weeks salmon consumption | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02122198 -
Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
|
N/A | |
Completed |
NCT02502812 -
Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04216342 -
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03654313 -
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
|
Phase 1 | |
Completed |
NCT03646656 -
Heart Health Buddies: Peer Support to Decrease CVD Risk
|
N/A | |
Completed |
NCT02081066 -
Identification of CETP as a Marker of Atherosclerosis
|
N/A | |
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT06405880 -
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
|
N/A | |
Recruiting |
NCT03095261 -
Incentives in Cardiac Rehabilitation
|
N/A | |
Completed |
NCT02868710 -
Individual Variability to Aerobic Exercise Training
|
N/A | |
Not yet recruiting |
NCT02578355 -
National Plaque Registry and Database
|
N/A | |
Completed |
NCT02998918 -
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
|
N/A | |
Completed |
NCT02711878 -
Healing Hearts and Mending Minds in Older Adults Living With HIV
|
N/A | |
Completed |
NCT02589769 -
Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons
|
N/A | |
Recruiting |
NCT02885792 -
Coronary Artery Disease in Patients Suffering From Schizophrenia
|
N/A | |
Completed |
NCT02657382 -
Mental Stress Ischemia: Biofeedback Study
|
N/A | |
Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A | |
Completed |
NCT02272946 -
Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk
|
Phase 2 | |
Completed |
NCT02640859 -
Investigation of Metabolic Risk in Korean Adults
|
||
Recruiting |
NCT02265250 -
Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
|